Evidence map›Paper›PMID 34906585›Full record

ArticleUrology2022

Urinary MyProstateScore (MPS) to Rule out Clinically-Significant Cancer in Men with Equivocal (PI-RADS 3) Multiparametric MRI: Addressing an Unmet Clinical Need.

Jeffrey J Tosoian, Udit Singhal, Matthew S Davenport, John T Wei, Jeffrey S Montgomery, Arvin K George, Simpa S Salami, Stanley G Mukundi, Javed Siddiqui, Lakshmi P Kunju and 15 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Urology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.3field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Biomarkers of Aggressive Prostate Cancer at Diagnosis.International journal of molecular sciences · 2023
    Review
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 7 institutions in 2 countries.

Jeffrey J TosoianDepartment of Urology, Vanderbilt University, Nashville, TN; Vanderbilt-Ingram Cancer Center, Nashville, TN; Department of Urology, University of Michigan, Ann Arbor, MI; Rogel Cancer Center, University of Michigan, Ann Arbor, MI; Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI. Electronic address: jeff.tosoian@vumc.org.
Udit SinghalDepartment of Urology, University of Michigan, Ann Arbor, MI; Rogel Cancer Center, University of Michigan, Ann Arbor, MI; Department of Urology, Mayo Clinic, Rochester, MN.
Matthew S DavenportDepartment of Urology, University of Michigan, Ann Arbor, MI; Department of Radiology, University of Michigan, Ann Arbor, MI.
John T WeiDepartment of Urology, University of Michigan, Ann Arbor, MI.
Jeffrey S MontgomeryDepartment of Urology, University of Michigan, Ann Arbor, MI; Rogel Cancer Center, University of Michigan, Ann Arbor, MI.
Arvin K GeorgeDepartment of Urology, University of Michigan, Ann Arbor, MI; Rogel Cancer Center, University of Michigan, Ann Arbor, MI.
Simpa S SalamiDepartment of Urology, University of Michigan, Ann Arbor, MI; Rogel Cancer Center, University of Michigan, Ann Arbor, MI.
Stanley G MukundiDepartment of Urology, University of Michigan, Ann Arbor, MI.
Javed SiddiquiMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI.
Lakshmi P KunjuDepartment of Pathology, University of Michigan, Ann Arbor, MI.
Benjamin P TookeUniversity of Michigan Medical School, Ann Arbor, MI.
C Yoonhee RyderUniversity of Michigan Medical School, Ann Arbor, MI.
Sarah P DuganUniversity of Michigan Medical School, Ann Arbor, MI.
Zoey ChopraUniversity of Michigan Medical School, Ann Arbor, MI.
Rachel BotbylMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI.
Yilin FengUniversity of Michigan Medical School, Ann Arbor, MI.
Michael S SessineDepartment of Urology, Wayne State University, Detroit, MI.
Nicholas W EyrichDepartment of Urology, Emory University, Atlanta, GA.
Ashley E RossDepartment of Urology, Northwestern Feinberg School of Medicine, Chicago, IL.
Bruce J TrockDepartment of Urology, Johns Hopkins School of Medicine, Baltimore, MD.
Scott A TomlinsMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI; Department of Pathology, University of Michigan, Ann Arbor, MI.
Ganesh S PalapattuDepartment of Urology, University of Michigan, Ann Arbor, MI; Rogel Cancer Center, University of Michigan, Ann Arbor, MI; Department of Urology, Medical University of Vienna, Vienna, Austria.
Arul M ChinnaiyanDepartment of Urology, University of Michigan, Ann Arbor, MI; Rogel Cancer Center, University of Michigan, Ann Arbor, MI; Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI; Department of Pathology, University of Michigan, Ann Arbor, MI; Howard Hughes Medical Institute, University of Michigan, Ann Arbor, MI.
Yashar S NiknafsMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI.
Todd M MorganDepartment of Urology, University of Michigan, Ann Arbor, MI; Rogel Cancer Center, University of Michigan, Ann Arbor, MI.
University of Michigan · USEmory University · USHoward Hughes Medical Institute · USJohns Hopkins University · USNorthwestern University · USVanderbilt University · USWayne State University · US

Funding

MICHIGAN MEDICAL SCIENTIST TRAINING PROGRAMT32GM007863 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI COLLINS, KATHLEEN L. · 1985 to 2024
$38.3M
Tissue/InformaticsP50CA186786 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Ganesh S Palapattu · 2014 to 2026
$27.6M
Exploring Precision Oncology: From Gene Fusions to lncRNAsR35CA231996 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CHINNAIYAN, ARUL M · 2018 to 2024
$6.4M
Advanced Training in Urologic OncologyT32CA180984 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Ganesh S Palapattu, VAHAKN B SHAHINIAN · 2014 to 2026
$3.4M
Discovery and qualification of transcriptomic biomarkers for the early detection of aggressive prostate cancerU01CA214170 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CHINNAIYAN, ARUL M · 2016 to 2021
$3.3M
NCI NIH HHS L30 CA264387NCI NIH HHS P50 CA186786NCI NIH HHS R35 CA231996NCI NIH HHS T32 CA180984NCI NIH HHS U01 CA214170NIGMS NIH HHS T32 GM007863
6 · The paper itself

Abstract

objectiveTo evaluate the complementary value of urinary MyProstateScore (MPS) testing and multiparametric MRI (mpMRI) and assess outcomes in patients with equivocal mpMRI. MATERIALS AND

methodsIncluded patients underwent mpMRI followed by urine collection and prostate biopsy at the University of Michigan between 2015 -2019. MPS values were calculated from urine specimens using the validated model based on serum PSA, urinary PCA3, and urinary TMPRSS2:ERG. In the PI-RADS 3 population, the discriminative accuracy of PSA, PSAD, and MPS for GG≥2 cancer was quantified by the AUC curve. Decision curve analysis was used to assess net benefit of MPS relative to PSAD.

resultsThere were 540 patients that underwent mpMRI and biopsy with MPS available. The prevalence of GG≥2 cancer was 13% for PI-RADS 3, 56% for PI-RADS 4, and 87% for PI-RADS 5. MPS was significantly higher in men with GG≥2 cancer [median 44.9, IQR (29.4 -57.5)] than those with negative or GG1 biopsy [median 29.2, IQR (14.8 -44.2); P <.001] in the overall population and when stratified by PI-RADS score. In the PI-RADS 3 population (n = 121), the AUC for predicting GG≥2 cancer was 0.55 for PSA, 0.62 for PSAD, and 0.73 for MPS. MPS provided the highest net clinical benefit across all pertinent threshold probabilities.

conclusionIn patients that underwent mpMRI and biopsy, MPS was significantly associated with GG≥2 cancer across all PI-RADS scores. In the PI-RADS 3 population, MPS significantly outperformed PSAD in ruling out GG≥2 cancer. These findings suggest a complementary role of MPS testing in patients that have undergone mpMRI.

Indexed as

Multiparametric Magnetic Resonance ImagingProstatic NeoplasmsHumansMagnetic Resonance ImagingMaleProstate-Specific AntigenRetrospective StudiesProstate-Specific Antigen

Identifiers

PMID34906585
PMCPMC10171463
OpenAlexW4200399130

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.